Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of SA58 Nasal Spray in Close Contacts of COVID-19
NCT05667714Unknown
- Sponsor
- Sinovac Life Sciences
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Inhalation Devices, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, single-blind trial of SA58 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Sinovac Life Sciences. Primary endpoint: Incidence of symptomatic COVID-19 cases at 30 days. Status: unknown.
02
Drugs
SA58
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05667714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667714.